Nov 18 (Reuters) - Contineum Therapeutics Inc :
* CONTINEUM THERAPEUTICS EXPANDS CLINICAL DEVELOPMENT OF PIPE-791 WITH FDA AUTHORIZATION OF ITS INVESTIGATIONAL NEW DRUG $(IND.AU)$ APPLICATION FOR CHRONIC PAIN
* CONTINEUM THERAPEUTICS INC: PHASE 1B STUDY FOR POTENTIAL TREATMENT OF OSTEOARTHRITIS AND LOW BACK PAIN EXPECTED TO COMMENCE IN Q1 OF 2025
* CONTINEUM THERAPEUTICS INC - PHASE 1B STUDY FOR PIPE-791 TO BEGIN IN Q1 2025
* CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791 STUDY EXPECTED IN EARLY 2026
* CONTINEUM THERAPEUTICS INC - EXPECTS $213.9 MILLION CASH TO FUND OPERATIONS THROUGH 2027
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。